Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials

Abstract

Summary Background A ring-shaped, contraceptive vaginal system designed to last 1 year (13 cycles) delivers an average of 0·15 mg segesterone acetate and 0·013 mg ethinylestradiol per day. We evaluated the efficacy of this contraceptive vaginal system and return to menses or pregnancy after use. Methods In two identically designed, multicentre, open-label, single-arm, phase 3 trials (one at 15 US academic and community sites and one at 12 US and international academic and community sites), participants followed a 21-days-in, 7-days-out segesterone acetate and ethinylestradiol contraceptive vaginal system schedule for up to 13 cycles. Participants were healthy, sexually active, non-pregnant, non-sterilised women aged 18–40 years. Women were cautioned that any removals during the 21 days of cyclic use should not exceed 2 h, and used daily paper diaries to record vaginal system use. Consistent with regulatory requirements for contraceptives, we calculated the Pearl Index for women aged 35 years and younger, excluding adjunctive contraception cycles, as the primary efficacy outcome measure. We also did intention-to-treat Kaplan-Meier life table analyses and followed up women who did not use hormonal contraceptives or desired pregnancy after study completion for 6 months for return to menses or pregnancy. The trials are registered with ClinicalTrials.gov , numbers NCT00455156 and NCT00263341 . Findings Between Dec 19, 2006, and Oct 9, 2009, at the 15 US sites, and between Nov 1, 2006, and July 2, 2009, at the 12 US and international sites we enrolled 2278 women. Our overall efficacy analysis included 2265 participants (1130 in the US study and 1135 in the international study) and 1303 (57·5%) participants completed up to 13 cycles. The Pearl Index for the primary efficacy group was 2·98 (95% CI 2·13–4·06) per 100 woman-years, and was well within the range indicative of efficacy for a contraceptive under a woman's control. The Kaplan-Meier analysis revealed the contraceptive vaginal system was 97·5% effective, which provided further evidence of efficacy. Pregnancy occurrence was similar across cycles. All 290 follow-up participants reported return to menses or became pregnant (24 [63%] of 38 women who desired pregnancy) within 6 months. Interpretation The segesterone acetate and ethinylestradiol contraceptive vaginal system is an effective contraceptive for 13 consecutive cycles of use. This new product adds to the contraceptive method mix and the 1-year duration of use means that women do not need to return to the clinic or pharmacy for refills every few months. Funding Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health, the US Agency for International Development, and the WHO Reproductive Health Research Department.

Climate change and contraception

“…User-controlled methods such as vaginal rings have become popular. A novel contraceptive vaginal system (Annovera) for 1 year of use is expected to become available in the USA by the end of 2019 15 16…”

<p>Choosing and Using the Progesterone Vaginal Ring: Women’s Lived Experiences in Three African Cities</p>

“…Related to the importance of convenience is the issue of side effects. For women in this study and in other studies (whether Africa-based 23 or beyond 24,25 ), perceptions around, and personal experiences of, side effects serve as a deterrent to the uptake of specific methods, and are voiced as a major concern. This calls for thorough family planning counseling around new and existing methods to ensure that myths are dispelled, expectations are grounded in reality/science, and remedies for potential side effects are well understood by women in advance of their becoming users of a particular method.…”

Dose-finding study of a 90-day contraceptive vaginal ring releasing estradiol and segesterone acetate

“…In addition, concerns regarding unfavorable bleeding profiles led to addition of estrogen during ring development. Subsequently, a contraceptive vaginal system releasing ethinyl estradiol 13 mcg/day and SA 150 mcg/day for cyclic use over one year has recently received FDA approval, offering women a user-controlled, combined hormonal method with a longer duration of action compared with other available combined hormonal methods [3][4][5].…”